Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
354.5 USD | -0.01% | +0.59% | +18.37% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.52 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.37% | 101B | B- | ||
+13.93% | 125B | A- | ||
-0.28% | 39.69B | B- | ||
-33.18% | 36.86B | A- | ||
-5.28% | 20.05B | B- | ||
-13.82% | 3.08B | C+ | ||
-39.49% | 993M | B- | ||
-28.58% | 337M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CI Stock
- Ratings Cigna